Cargando…
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
Optimal blood glucose control helps reduce the development of the complications of type II diabetes mellitus (T2DM). T2DM patients usually are at increased risk of cardiovascular (CV) events and mortality. Therapies and strategies to treat diabetes and its related CV outcomes still need more investi...
Autores principales: | Aftab, Saba, Vetrivel Suresh, Rishwanth, Sherali, Nazleen, Daniyal, Muhammad, Tsouklidis, Nicholas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535950/ https://www.ncbi.nlm.nih.gov/pubmed/33042651 http://dx.doi.org/10.7759/cureus.10783 |
Ejemplares similares
-
Choroidal Changes in Diabetic Patients With Different Stages of Diabetic Retinopathy
por: Hamadneh, Tariq, et al.
Publicado: (2020) -
Exploring the Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Expanding Horizons Beyond Diabetes Management
por: Fatima, Aroob, et al.
Publicado: (2023) -
Integration of Next-Generation Sequencing in Diagnosing and Minimal Residual Disease Detection in Patients With Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
por: Sherali, Nazleen, et al.
Publicado: (2020) -
Understanding Cognitive Deficit After Subarachnoid Hemorrhage: A Memory Focused Approach
por: Alfonso, Michael, et al.
Publicado: (2020) -
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)